Can Novo Nordisk get its comeback going in 2026? Let's discuss two things that could materialize for the company next year ...

Eli Lilly’s weight loss drugs have delivered blockbuster sales in recent quarters. The company is a leader in this market ...

FDA may expedite approval timeline for Eli Lilly's weight-loss treatment, potentially moving decision date to late March from ...

Bank of America sees Eli Lilly's obesity drug growth underestimated, forecasting $3 billion Orfoglipron revenue by 2026 as new therapies expand global market leadership.

Eli Lilly's innovation and pipeline diversification support long-term growth, despite patent risks and competition. Read more ...

Novo Nordisk NVO announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) ...

A promising obesity and diabetes drug stumbles in Alzheimer's trials, rattling markets. Did investors overreact, or is this a reset for long-term opportunity?

In an added benefit, more than one in eight people taking the highest dose of Retratrutide were completely free of arthritic ...

Eli Lilly will cut prices for its weight loss drug Zepbound, with single-dose vials now available for $299 per month through ...

Eli Lilly said on Thursday its next-generation obesity drug helped patients lose an average of 28.7% of their weight in a ...

Retatrutide, the next generation of GLP-1 drug from Eli Lilly, helped participants lose an average of 71.2 pounds and reduce ...